Donald Woytowitz

944 total citations
19 papers, 731 citations indexed

About

Donald Woytowitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Donald Woytowitz has authored 19 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Hematology. Recurrent topics in Donald Woytowitz's work include Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Research Studies (5 papers) and Multiple Myeloma Research and Treatments (3 papers). Donald Woytowitz is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Research Studies (5 papers) and Multiple Myeloma Research and Treatments (3 papers). Donald Woytowitz collaborates with scholars based in United States, Germany and Belgium. Donald Woytowitz's co-authors include Martin R. Weber, Thomas J. Lynch, Michael McCleod, Taral Patel, Luke Dreisbach, W. Heim, Robert C. Hermann, Shaker R. Dakhil, Eugene Paschold and Nicholas Iannotti and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Donald Woytowitz

17 papers receiving 705 citations

Peers

Countries citing papers authored by Donald Woytowitz

Since Specialization

Citations

This map shows the geographic impact of Donald Woytowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Woytowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Woytowitz more than expected).

Fields of papers citing papers by Donald Woytowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald Woytowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Woytowitz. The network helps show where Donald Woytowitz may publish in the future.

Co-authorship network of co-authors of Donald Woytowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Donald Woytowitz. A scholar is included among the top collaborators of Donald Woytowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald Woytowitz. Donald Woytowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	A Case Series of Antiphospholipid Syndrome Patients 2016 ·Blood ·Michael D. Macklin, Donald Woytowitz	0
2	Recurrent Mixed Cryoglobulinemia (MCS): A Case Report and Literature Review. 2015 ·PubMed ·(unknown), Donald Woytowitz, (unknown), Sheldon Bastacky, (unknown), James R. Johnston, Jose Bernardo	4
3	Chronic myelogenous leukemia in eastern Pennsylvania: an assessment of registry reporting. 2015 ·PubMed ·Kristen J. Mertz, Jeanine M. Buchanich, (unknown), (unknown), Donald Woytowitz, Roy E. Smith	1
4	Tacrolimus-Induced Refractory Immune Thrombocytopenia In Solid Organ Transplant Patients 2013 ·Blood ·Aju Mathew, Donald Woytowitz, Roy E. Smith, (unknown)	5
5	IV iron sucrose for cancer and/or chemotherapy-induced anemia in patients treated with erythropoiesis-stimulating agents 2011 ·Community Oncology ·Lowell Anthony, Nashat Gabrail, Hassan Ghazal, Donald Woytowitz, Marshall S. Flam, Anibal Drelichman, David Loesch, (unknown), Antoinette Mangione	11
6	Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099 2010 ·Journal of Clinical Oncology ·Thomas J. Lynch, Taral Patel, Luke Dreisbach, Michael McCleod, W. Heim, Robert C. Hermann, Eugene Paschold, Nicholas Iannotti, Shaker R. Dakhil, (unknown), (unknown), Martin R. Weber, Donald Woytowitz	338
7	Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen 2009 ·European Journal Of Haematology ·James R. Berenson, Ori Yellin, Donald Woytowitz, Marshall S. Flam, Alan Cartmell, Ravi Patel, (unknown), Youram Nassir, (unknown), (unknown), (unknown), Regina A. Swift	21
8	K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial 2009 ·Journal of Clinical Oncology ·Shirin Khambata‐Ford, Christopher Harbison, Donald Woytowitz, (unknown), Christine E. Horak, (unknown), Shaker R. Dakhil, Robert C. Hermann, Thomas J. Lynch, Martin R. Weber	17
9	Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line advanced NSCLC: Analysis of the BMS099 trial 2009 ·Journal of Clinical Oncology ·Taral Patel, Luke Dreisbach, Michael McCleod, W. Heim, Robert C. Hermann, Donald Woytowitz, Haolan Lu, Martin R. Weber, Thomas J. Lynch	2
10	Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer 2008 ·Journal of Clinical Oncology ·Christian Manegold, Donald Gravenor, Donald Woytowitz, J. Mezger, Vera Hirsh, Gary Albert, Mohammed Al-Adhami, David Readett, Arthur Μ. Krieg, Cynthia G. Leichman	129
11	Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL) 2008 ·Journal of Clinical Oncology ·James R. Berenson, Ori Yellin, Ralph V. Boccia, Marshall S. Flam, Stephen Heung‐Sang Wong, Olcay Batuman, (unknown), Donald Woytowitz, (unknown), Youram Nassir, (unknown)	2
12	Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss 2008 ·Clinical Cancer Research ·James R. Berenson, Ori Yellin, Ralph V. Boccia, Marshall S. Flam, Siu‐Fun Wong, Olcay Batuman, Mehdi M. Moezi, Donald Woytowitz, (unknown), Youram Nassir, Regina A. Swift	50
13	B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Thomas J. Lynch, Taral Patel, Luke Dreisbach, Michael McCleod, W. Heim, (unknown), (unknown), (unknown), Martin R. Weber, Donald Woytowitz	70
14	A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy 2007 ·Journal of Clinical Oncology ·Robert E. Bellet, Hassan Ghazal, Marshall S. Flam, Anibal Drelichman, N. Gabrail, Donald Woytowitz, Danuta Z. Loesch, (unknown), Antoinette Mangione, Lowell Anthony, (unknown)	16
15	Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen. 2007 ·Blood ·James R. Berenson, Ori Yellin, Donald Woytowitz, Marshall S. Flam, Alan Cartmell, Ravi Patel, (unknown), Youram Nassir, Regina A. Swift	8
16	Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Research Network 2006 ·Journal of Clinical Oncology ·Jeffrey Patton, David R. Spigel, F. Anthony Greco, William H. Liggett, (unknown), (unknown), Marshall T. Schreeder, Donald Woytowitz, Eric C. Nelson, John D. Hainsworth	26
17	CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study 2005 ·Journal of Clinical Oncology ·(unknown), Donald Gravenor, Donald Woytowitz, J. Mezger, Gary Albert, Tess Schmalbach, Mohammed Al-Adhami, C. Manegold	17
18	PD-046 Phase II randomized trial adding a toll-like receptor 9 agonist (ProMuneTM) to first line chemotherapy shows improved response in advanced non-small cell lung cancer 2005 ·Lung Cancer ·C. Manegold, (unknown), Donald Gravenor, Donald Woytowitz, J. Mezger, (unknown), Mohammed Al-Adhami, Tess Schmalbach, John K. Whisnant	1
19	Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network 2005 ·Journal of Clinical Oncology ·Eric Raefsky, David R. Spigel, F. Anthony Greco, Denise A. Yardley, James E. Bradof, Donald Woytowitz, Marshall T. Schreeder, William H. Liggett, (unknown), D Petrone, John D. Hainsworth	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact